NARA Discovery
Article Details
← Back to Search Results
Journal Article

Bile acids in Alzheimer’s disease: a double-edged sword in gut–liver–brain signaling and neurodegeneration

Rehana Basri; Hayder M. Al-kuraishy; Mubarak Alruwaili; Ali I. Al-Gareeb; Ali K. Albuhadily; Athanasios Alexiou; Marios Papadakis; Safaa A. Faheem; Gaber El-Saber Batiha
Naunyn-Schmiedeberg's Archives of Pharmacology · Vol. 399, Issue 11 · pp. 16841-16859 · 2026

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) deposition, tau pathology, synaptic dysfunction, neuroinflammation, and metabolic impairment. Increasing evidence suggests that bile acids, traditionally recognized for their roles in lipid digestion and hepatic metabolism, act as endocrine signaling molecules that influence central nervous system (CNS) homeostasis. Through enterohepatic circulation and microbiota-dependent biotransformation, bile acid composition is dynamically regulated and can modulate peripheral metabolic and immune pathways with downstream effects on the brain. Notably, bile acid signaling via key receptors such as the farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor 5 and G-protein-coupled bile acid receptor 1 (TGR5/GPBAR1) has emerged as a mechanistic bridge linking liver–gut physiology to neuroinflammatory and neurodegenerative processes. Altered bile acid profiles have been reported in AD and mild cognitive impairment, with accumulating findings suggesting that hydrophobic secondary bile acids may contribute to blood–brain barrier (BBB) disruption and neurotoxicity. In contrast, hydrophilic bile acids may exert neuroprotective and anti-inflammatory effects. In addition, bile acids drive the release of gut hormones such as glucagon-like peptide 1 (GLP-1) and fibroblast growth factor 19 (FGF19), highlighting indirect neurometabolic pathways relevant to cognition and neurodegeneration. This narrative review synthesizes current biochemical, experimental, and clinical evidence supporting a role for bile acid signaling in AD pathogenesis and progression. We discuss receptor-mediated pathways, microbiota-bile acid interactions, neuroimmune modulation, and translational perspectives, proposing that bile acid–based biomarkers and therapeutic strategies targeting FXR/TGR5 signaling may represent promising avenues for future AD intervention.

Bibliographic Information

JournalNaunyn-Schmiedeberg's Archives of Pharmacology
PublisherSpringer
Publication Date2026-08-01
Publication Year2026
Volume399
Issue11
Pages16841-16859
Document TypeJournal Article
Print ISSN0028-1298
eISSN1432-1912
DOI10.1007/s00210-026-05516-1

Access Information

NARA Access Coverage1873-01-01~Current
Journal Homepagehttps://www.springer.com/journal/210
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.